Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (41-50 of 208) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2012
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)Jenny Wu, Peter H Clingen, Victoria J Spanswick, et al.
Cancer Immunology Research|March 12, 2016
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 TherapyAllison R Greenplate, Douglas B Johnson, Mikael Roussel, et al.
Head & Neck|July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinomaChristine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
British Journal of Cancer|July 30, 2019
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.
Journal of Translational Medicine|May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
Case Reports in Oncology|April 24, 2019
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureNikhil Agrawal, Arjun Khunger, Pankit Vachhani, et al.
The Oncologist|May 25, 2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Maryann Kwa, Robert Baumgartner, Linda Shavit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targetsYingjun Su, Katayoun I Amiri, Linda W Horton, et al.
Cancer Immunology Research|February 5, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterDouglas B Johnson, Debra L Friedman, Elizabeth Berry, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Pageof 21

Showing results (41-50 of 208) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2012
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)Jenny Wu, Peter H Clingen, Victoria J Spanswick, et al.
Cancer Immunology Research|March 12, 2016
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 TherapyAllison R Greenplate, Douglas B Johnson, Mikael Roussel, et al.
Head & Neck|July 24, 2010
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinomaChristine H Chung, Paula R Pohlmann, Mace L Rothenberg, et al.
British Journal of Cancer|July 30, 2019
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.
Journal of Translational Medicine|May 12, 2019
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018Paolo A Ascierto, Paolo Bruzzi, Alexander Eggermont, et al.
Case Reports in Oncology|April 24, 2019
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureNikhil Agrawal, Arjun Khunger, Pankit Vachhani, et al.
The Oncologist|May 25, 2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Maryann Kwa, Robert Baumgartner, Linda Shavit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targetsYingjun Su, Katayoun I Amiri, Linda W Horton, et al.
Cancer Immunology Research|February 5, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterDouglas B Johnson, Debra L Friedman, Elizabeth Berry, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Pageof 21